BI
CTMX icon

BVF Inc’s CytomX Therapeutics CTMX Stock Holding History

BVF Inc’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,228,461
Closed -$3.32M – 46
2025
Q1 		$3.32M Hold
5,228,461
– – 0.14% 43
2024
Q4 		$5.39M Hold
5,228,461
– – 0.18% 44
2024
Q3 		$6.17M Hold
5,228,461
– – 0.18% 39
2024
Q2 		$6.38M Sell
5,228,461
-1,367,340
-21% -$2.72M 0.18% 42
2024
Q1 		$14.4M Hold
6,595,801
– – 0.4% 36
2023
Q4 		$10.2M Hold
6,595,801
– – 0.26% 48
2023
Q3 		$8.51M Hold
6,595,801
– – 0.23% 48
2023
Q2 		$11.3M Hold
6,595,801
– – 0.32% 45
2023
Q1 		$9.96M Hold
6,595,801
– – 0.36% 48
2022
Q4 		$10.6M Hold
6,595,801
– – 0.45% 49
2022
Q3 		$9.56M Buy
6,595,801
+792,101
+14% +$1.22M 0.4% 52
2022
Q2 		$10.6M Hold
5,803,700
– – 0.51% 50
2022
Q1 		$15.5M Hold
5,803,700
– – 0.62% 43
2021
Q4 		$25.1M Buy
+5,803,700
New +$34M 0.91% 31
2021
Q2 		– Sell
-5,576,471
Closed -$43.1M – 71
2021
Q1 		$43.1M Hold
5,576,471
– – 1.62% 22
2020
Q4 		$36.5M Buy
5,576,471
+2,016,749
+57% +$14.4M 1.44% 25
2020
Q3 		$23.7M Buy
3,559,722
+444,185
+14% +$3.29M 1.29% 26
2020
Q2 		$26M Sell
3,115,537
-806,436
-21% -$7.49M 1.6% 24
2020
Q1 		$30.1M Buy
3,921,973
+3,155,825
+412% +$22M 2.8% 13
2019
Q4 		$6.37M Sell
766,148
-1,111,000
-59% -$7.5M 0.48% 38
2019
Q3 		$13.9M Buy
1,877,148
+3,531
+0.2% +$34.8K 1.46% 23
2019
Q2 		$21M Buy
1,873,617
+675,617
+56% +$7.08M 2.3% 14
2019
Q1 		$12.9M Buy
+1,198,000
New +$17.7M 1.44% 25
2018
Q1 		– Sell
-1,124,483
Closed -$23.7M – 44
2017
Q4 		$23.7M Sell
1,124,483
-1,106,415
-50% -$22.9M 2.86% 11
2017
Q3 		$40.5M Buy
2,230,898
+203,900
+10% +$3.18M 5.15% 8
2017
Q2 		$31.4M Buy
2,026,998
+222,323
+12% +$3.35M 4.88% 7
2017
Q1 		$31.2M Buy
1,804,675
+1,249,869
+225% +$16.4M 5.3% 6
2016
Q4 		$6.1M Sell
554,806
-37,007
-6% -$448K 1.23% 20
2016
Q3 		$9.28M Sell
591,813
-14,325
-2% -$173K 1.75% 16
2016
Q2 		$6.19M Hold
606,138
– – 1.32% 21
2016
Q1 		$7.82M Sell
606,138
-2,710
-0.4% -$37.6K 1.93% 19
2015
Q4 		$12.7M Buy
+608,848
New +$9.63M 2.17% 16

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BVF Inc's CTMX Position: Q2 2025 in Review

BVF Inc sold out of CytomX Therapeutics (CTMX) in Q2 2025, closing a stake of 5,228,461 shares — an estimated $3.32M sold.

BVF Inc first reported a position in CTMX in Q4 2015 and held it in 32 quarters. The position peaked at $43.1M in Q1 2021. 83 funds tracked by Wall St. Rank hold CTMX as of Q2 2025.

  • BVF Inc reported no remaining CytomX Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BVF Inc sold 5,228,461 CytomX Therapeutics shares in Q2 2025, an estimated $3.32M.
  • BVF Inc first reported a position in CytomX Therapeutics in Q4 2015 and held it in 32 quarters.
  • BVF Inc's CytomX Therapeutics position peaked at $43.1M in Q1 2021.
  • 83 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2025.

Based on BVF Inc's 13F filing for Q2 2025, filed 14 Aug 2025.